drugset / Trial / NCT02189343
Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma
NaSingle-groupOpen-labelOther
Summary
To determine the maximum tolerated dose (MTD), if present, and dose schedule of ACY-1215 (ricolinostat) in combination with pomalidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma.
Timeline
- Start
- 2014-09-15
- Primary completion
- 2018-04-18
- Completion
- 2018-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | — | — |
| Subject | Pomalidomide | Other / unclassified | — | — |
| Subject | Ricolinostat | Small molecule | — | — |